Hanx Biopharmaceuticals (Wuhan) (HKG:3378) entered into strategic cooperation and platform use license agreements with Shenzhen XtalPi Technology.
The parties intend to explore the application of AI for science in fields such as antibody design, innovative molecule design, and drug R&D process optimization, a Monday bourse filing showed.
Under the contract, the company will procure and use the relevant services of the XtalPi Science platform, while XtalPi will provide its with the necessary platform capabilities and technical support.
Shenzhen XtalPi Technology is a unit of biotech company XtalPi (HKG:2228).